Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies

P. Correale, D. Cerretani, M. Clerici, S. Messinese, S. Marsili, R. Petrioli, F. Cetta, V. Savelli, A. Guarnieri, E. Pinto, G. Giorgi, G. Francini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This phase II clinical trial was performed in order to evaluate the pharmacokinetics, toxicity and anti-tumor activity of a novel combination of gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) designed on a specific translational basis. Every 4 weeks, 44 patients with various gastroenteric malignancies, 29 of whom had pancreas carcinoma, received a short intravenous (i.v.) infusion of FA (100 mg/m2) and 5-FU (400 mg/m 2) on days 1-5, and GEM 1000 mg/m2 on days 1, 8 and 16. Our results suggest that, although this treatment leads to hematological and gastroenteric toxicity, it is very active in patients with pancreatic carcinoma. We therefore believe that an improved version would merit further investigation in larger scale trials.

Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalJournal of Chemotherapy
Volume16
Issue number2
Publication statusPublished - Apr 2004

Fingerprint

gemcitabine
Leucovorin
Fluorouracil
Phase II Clinical Trials
Intravenous Infusions
Pancreas
Neoplasms
Pharmacokinetics
Carcinoma
Therapeutics

Keywords

  • 5-Fluorouracil
  • Gastroenteric malignancies
  • Gemcitabine
  • Pancreas carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Correale, P., Cerretani, D., Clerici, M., Messinese, S., Marsili, S., Petrioli, R., ... Francini, G. (2004). Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies. Journal of Chemotherapy, 16(2), 206-210.

Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies. / Correale, P.; Cerretani, D.; Clerici, M.; Messinese, S.; Marsili, S.; Petrioli, R.; Cetta, F.; Savelli, V.; Guarnieri, A.; Pinto, E.; Giorgi, G.; Francini, G.

In: Journal of Chemotherapy, Vol. 16, No. 2, 04.2004, p. 206-210.

Research output: Contribution to journalArticle

Correale, P, Cerretani, D, Clerici, M, Messinese, S, Marsili, S, Petrioli, R, Cetta, F, Savelli, V, Guarnieri, A, Pinto, E, Giorgi, G & Francini, G 2004, 'Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies', Journal of Chemotherapy, vol. 16, no. 2, pp. 206-210.
Correale P, Cerretani D, Clerici M, Messinese S, Marsili S, Petrioli R et al. Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies. Journal of Chemotherapy. 2004 Apr;16(2):206-210.
Correale, P. ; Cerretani, D. ; Clerici, M. ; Messinese, S. ; Marsili, S. ; Petrioli, R. ; Cetta, F. ; Savelli, V. ; Guarnieri, A. ; Pinto, E. ; Giorgi, G. ; Francini, G. / Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies. In: Journal of Chemotherapy. 2004 ; Vol. 16, No. 2. pp. 206-210.
@article{12994bbbf980401e9d5273a83c3b0e81,
title = "Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies",
abstract = "This phase II clinical trial was performed in order to evaluate the pharmacokinetics, toxicity and anti-tumor activity of a novel combination of gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) designed on a specific translational basis. Every 4 weeks, 44 patients with various gastroenteric malignancies, 29 of whom had pancreas carcinoma, received a short intravenous (i.v.) infusion of FA (100 mg/m2) and 5-FU (400 mg/m 2) on days 1-5, and GEM 1000 mg/m2 on days 1, 8 and 16. Our results suggest that, although this treatment leads to hematological and gastroenteric toxicity, it is very active in patients with pancreatic carcinoma. We therefore believe that an improved version would merit further investigation in larger scale trials.",
keywords = "5-Fluorouracil, Gastroenteric malignancies, Gemcitabine, Pancreas carcinoma",
author = "P. Correale and D. Cerretani and M. Clerici and S. Messinese and S. Marsili and R. Petrioli and F. Cetta and V. Savelli and A. Guarnieri and E. Pinto and G. Giorgi and G. Francini",
year = "2004",
month = "4",
language = "English",
volume = "16",
pages = "206--210",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies

AU - Correale, P.

AU - Cerretani, D.

AU - Clerici, M.

AU - Messinese, S.

AU - Marsili, S.

AU - Petrioli, R.

AU - Cetta, F.

AU - Savelli, V.

AU - Guarnieri, A.

AU - Pinto, E.

AU - Giorgi, G.

AU - Francini, G.

PY - 2004/4

Y1 - 2004/4

N2 - This phase II clinical trial was performed in order to evaluate the pharmacokinetics, toxicity and anti-tumor activity of a novel combination of gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) designed on a specific translational basis. Every 4 weeks, 44 patients with various gastroenteric malignancies, 29 of whom had pancreas carcinoma, received a short intravenous (i.v.) infusion of FA (100 mg/m2) and 5-FU (400 mg/m 2) on days 1-5, and GEM 1000 mg/m2 on days 1, 8 and 16. Our results suggest that, although this treatment leads to hematological and gastroenteric toxicity, it is very active in patients with pancreatic carcinoma. We therefore believe that an improved version would merit further investigation in larger scale trials.

AB - This phase II clinical trial was performed in order to evaluate the pharmacokinetics, toxicity and anti-tumor activity of a novel combination of gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) designed on a specific translational basis. Every 4 weeks, 44 patients with various gastroenteric malignancies, 29 of whom had pancreas carcinoma, received a short intravenous (i.v.) infusion of FA (100 mg/m2) and 5-FU (400 mg/m 2) on days 1-5, and GEM 1000 mg/m2 on days 1, 8 and 16. Our results suggest that, although this treatment leads to hematological and gastroenteric toxicity, it is very active in patients with pancreatic carcinoma. We therefore believe that an improved version would merit further investigation in larger scale trials.

KW - 5-Fluorouracil

KW - Gastroenteric malignancies

KW - Gemcitabine

KW - Pancreas carcinoma

UR - http://www.scopus.com/inward/record.url?scp=2942536831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942536831&partnerID=8YFLogxK

M3 - Article

C2 - 15216958

AN - SCOPUS:2942536831

VL - 16

SP - 206

EP - 210

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -